The human microbiome comprises an ample set of organisms that inhabit and interact within the human body, contributing both positively and negatively to our health. In recent years, several research ...groups have described the presence of microorganisms in organs or tissues traditionally considered as ‘sterile’ under healthy and pathological conditions. In this sense, microorganisms have been detected in several types of cancer, including those in ‘sterile’ organs. But how can the presence of microorganisms be detected? In most studies, 16S and internal transcribed spacer (ITS) ribosomal DNA (rDNA) sequencing has led to the identification of prokaryotes and fungi. However, a major limitation of this technique is that it cannot distinguish between living and dead organisms. RNA‐based methods have been proposed to overcome this limitation, as the shorter half‐life of the RNA would identify only the transcriptionally active microorganisms, although perhaps not all the viable ones. In this sense, metaproteomic techniques or the search for molecular metabolic signatures could be interesting alternatives for the identification of living microorganisms. In summary, new technological advances are challenging the notion of ‘sterile’ organs in our body. However, to date, evidence for a structured living microbiome in most of these organs is scarce or non‐existent. The implementation of new technological approaches will be necessary to fully understand the importance of the microbiome in these organs, which could pave the way for the development of a wide range of new therapeutic strategies.
Metabolic biomarkers, particularly glycated hemoglobin and fasting plasma glucose, are pivotal in the diagnosis and control of diabetes mellitus. Despite their importance, they exhibit limitations in ...assessing short-term glucose variations. In this study, we propose labile hemoglobin as an additional biomarker, providing insightful perspectives into these fluctuations. By utilizing datasets from 40,652 retrospective general participants and conducting glucose tolerance tests on 60 prospective pediatric subjects, we explored the relationship between plasma glucose and labile hemoglobin. A mathematical model was developed to encapsulate short-term glucose kinetics in the pediatric group. Applying dimensionality reduction techniques, we successfully identified participant subclusters, facilitating the differentiation between diabetic and non-diabetic individuals. Intriguingly, by integrating labile hemoglobin measurements with plasma glucose values, we were able to predict the likelihood of diabetes in pediatric subjects, underscoring the potential of labile hemoglobin as a significant glycemic biomarker for diabetes research.
Display omitted
•Retrospective and prospective study of diabetic biomarkers in over 40,000 individuals•Dimensionality reduction of the large individual dataset reveals diabetic subclusters•Labile hemoglobin identifies diabetic patients undetected by glycated hemoglobin alone•A mathematical model captures the dynamics of glucose, labile, and glycated hemoglobins
Classification description: Biological sciences; Human metabolism; Mathematical biosciences; Structures
Type 2 diabetes mellitus (DM2) is a disease of epidemic proportions. In the adult Spanish population, prevalence of DM2 is nearly 14%, which makes its monitoring and treatment imperative. Liraglutide ...has achieved relevance due to its efficacy and safety in DM treatment. The aim of this study is to gather expert opinion on diabetes to assess the current role of liraglutide in DM2.
The survey was performed by 57 internal medicine specialists using the Delphi method. The questionnaire had 56 items regarding liraglutide in DM treatment.
Consensus was reached in 71.4% of items. Panelists stated agreement regarding liraglutide suitability in the treatment of patients with DM2, high cardiovascular risk, and with pathologies related to obesity, highlighting its role in weight loss, low risk of hypoglycemia, and improvement of vascular risks. Moreover, consensus was not reached regarding the suitability of liraglutide in patients with special situations, mainly due to minimal experience caused by the small number of patients.
Due to its safety and hypoglycemic efficacy, liraglutide is an excellent choice for DM treatment in combination with other drugs. Its effects on the reduction of weight and other cardiovascular risk factors, make it an optimal treatment, especially in overweight or obese patients.
Knowledge of the features of patients with familial hypercholesterolaemia (FH) who are protected from atherosclerotic cardiovascular disease (ASCVD) is important for the clinical and prognostic care ...of this apparently high-risk condition. Our aim was to investigate the determinant and characteristics of patients with FH who are protected from ASCVD and have normal life expectancy, so-called 'resilient' FH (R-FH).
Spanish Familial Hypercholesterolaemia cohort study (SAFEHEART) is an open, multicentre, nation-wide, long-term prospective cohort study in genetically defined patients with heterozygous FH in Spain. Patients in the registry who at the time of analysis were at least 65 years or those who would have reached that age had they not died from an ASCVD event were analysed as a case-control study. Resilient FH was defined as the presence of a pathogenic mutation causative of FH in a patient aged ≥65 years without clinical ASCVD. Nine hundred and thirty registrants with FH met the study criteria. A defective low-density lipoprotein (LDL)-receptor mutation, higher plasma level of high-density lipoprotein cholesterol (HDL-C), younger age, female gender, absence of hypertension, and lower plasma lipoprotein (a) Lp(a) concentration were independently predictive of R-FH. In a second model, higher levels of HDL-C and lower 10-year score in SAFEHEART-RE were also independently predictive of R-FH.
Resilient FH may be typified as being female and having a defective LDL-receptor mutation, higher levels of plasma HDL-C, lower levels of Lp(a), and an absence of hypertension. The implications of this type of FH for clinical practice guidelines and the value for service design and optional care of FH remains to be established.
ClinicalTrials.gov number NCT02693548.
Some patients with COVID-19 have complex hypercoagulable abnormalities that are related to mortality. The optimal dosage of low molecular weight heparin in hospitalized patients with SARS-CoV-2 ...pneumonia is still not clear. Our objective is to evaluate the effects of adapting the dosage of low molecular weight heparin to thrombotic and bleeding risk scales in this setting. We performed a cohort, retrospective, observational, and analytical study at the Hospital Universitario of Jerez de la Frontera, with patients admitted with SARS-CoV-2 pneumonia from 1 October 2020 to 31 January 2021. They were classified according to whether they received prophylactic, intermediate, or therapeutic doses of enoxaparin. The primary endpoint was intrahospital mortality. Secondary endpoints were the need for invasive ventilation, thromboembolic events, bleeding, and the usefulness of thrombotic and bleeding scales. After binary logistic regression analysis, considering confounding variables, it was found that the use of enoxaparin at therapeutic doses was associated with lower mortality during admission compared to prophylactic and intermediate doses (RR 0.173; 95% CI, 0.038-0.8;
= 0.025). IMPROVE bleeding risk score correlated with a higher risk of minor bleeding (RR 1.263; 95% CI, 1.105-1.573;
= 0.037). In adult hospitalized patients with SARS-CoV-2 pneumonia presenting elevated D-dimer and severe proinflammatory state, therapeutic doses of enoxaparin can be considered, especially if bleeding risk is low according to the IMPROVE bleeding risk score.
Maximal doses of potent statins are the basement of treatment of familial hypercholesterolemia (FH). Little is known about the use of different statin regimens in FH.
The objectives of the study were ...to describe the treatment changes and low-density lipoprotein cholesterol (LDL-C) goal achievement with atorvastatin (ATV) and rosuvastatin (RV) in the SAFEHEART cohort, as well as to analyze the incidence of atherosclerotic cardiovascular events (ACVEs) and changes in the cardiovascular risk.
SAFEHEART is a prospective follow-up nationwide cohort study in a molecularly defined FH population. The patients were contacted on a yearly basis to obtain relevant changes in life habits, medication, and ACVEs.
A total of 1939 patients were analyzed. Median follow-up was 6.6 years (5–10). The estimated 10-year risk according the SAFEHEART risk equation was 1.61 (0.67–3.39) and 1.22 (0.54–2.93) at enrollment for ATV and RV, respectively (P < .001). There were no significant differences at the follow-up: 1.29 (0.54–2.82) and 1.22 (0.54–2.76) in the ATV and RV groups, respectively (P = .51). Sixteen percent of patients in primary prevention with ATV and 18% with RV achieved an LDL-C <100 mg/dL and 4% in secondary prevention with ATV and 5% with RV achieved an LDL-C <70 mg/dL. The use of ezetimibe was marginally greater in the RV group. One hundred sixty ACVEs occurred during follow-up, being its incidence rate 1.1 events/100 patient-years in the ATV group and 1.2 in the RV group (P = .58).
ATV and RV are 2 high-potency statins widely used in FH. Although the reduction in LDL-C levels was greater with RV than with ATV, the superiority of RV for reducing ACVEs was not demonstrated.
•This study analyzes event rates of 2 high-potency statins in FH.•LDL-C goal attainment and risk were similar in both groups.•LDL-C reduction was greater with rosuvastatin. Events were similar in both groups.•Event rate was 1.1/100 patient-years with atorvastatin and 1.2 with rosuvastatin.
ABSTRACT Background: Hypothyroidism is the most common condition linked to a hormone deficiency, nevertheless data on its prevalence are scarce in Spain. For that reason, we have estimated its ...prevalence through the registration of patients who had used thyroid hormones in Andalusia (South Spain). Method: data of patients who had withdrawn levothyroxine under the public system during 2014 from the base of the Andalusian Health Service were considered. Prevalence were calculated with confidence intervals of 95% for each management area, stratified by sex and age groups, and differences between them were evaluated. Results: 321,368 people (98% older than 18 years and 83% female) were identified as levothyroxine users and a prevalence of hypothyroidism of 3.95% (95%CI:3.94-3.96) was estimated for the general population. The condition was more common in females, in the older 18 years 7.81% (95%CI:7.80 to 7.82) compared to males 1.75% (95%CI:1.73-1.77) with a ratio of 4.5-fold. It increases in the population of women older than 45 years, 10.32% (95%CI:10.30-0.32) and in the over 60 years 11.37% (95%CI: 11.35-11.40). The prevalence in adult women in the western provinces is 7.38% (95%CI:7.36-7.40), in the eastern provinces 8.59% (95%CI:8.57-8.62) and in coastal areas 6.70% (95%CI: 6.68-6.72) compared to the mountainous ones, which is 8.91% (95%CI:8.88-8.94). Conclusion: The results denote a high prevalence of hypothyroidism in the adult population of Andalusia compared to the nearby countries, with a clear increased associated with females and age. Furthermore, the prevalence of the illness presents also a geographically-related variability.
RESUMEN Fundamento: El hipotiroidismo es la condición más común ligada a un déficit hormonal. A pesar de ello existe una escasez de datos en España sobre su su prevalencia. El objetivo fue estimar la prevalencia en Andalucía a través del registro de pacientes que consumieron hormona tiroidea durante el año 2014. Método: Se recuperaron los datos de las personas que habían retirado de la farmacia levotiroxina con cargo al sistema público durante 2014 de la base de datos del Servicio Andaluz de Salud. Se calcularon las prevalencias con sus intervalos de confianza del 95% para cada Área de Gestión, estratificadas por sexo y grupos etarios. Resultados: Se identificaron 321.368 personas (98% mayores de 18 años y 83% mujeres) consumidoras de levotiroxina y se estimó una prevalencia de hipotiroidismo del 3,95% (IC95%: 3,943,96) para población general. La condición era más común en la mujer, en mayores de 18 años un 7,81% (IC95 7,80 a 7,82) comparada con el hombre 1,75% (IC95 1,73 a 1,77) con una razón de 4,5. Aumenta en la población de mujeres mayores de 45 años, 10,32% (IC95 10,30 a 10,32) y más en las mayores de 60 años 11,37% (IC95%: 11,35 a 11,40). La prevalencia en mujer adulta de las provincias occidentales fue 7,38% (IC95%: 7,36-7,40), en las orientales de 8,59% (IC95%: 8,57-8,62) y en las áreas costeras fue de 6,70% (IC95%: 6,68-6,72) frente a las montañosas que fue 8,91% (IC95%: 8,88-8,94). Conclusión: Los resultados indican una elevada prevalencia de hipotiroidismo en la población adulta de Andalucía, con un claro predominio de la mujer y un incremento con la edad. Además, la prevalencia de la enfermedad también presenta una importante variabilidad geográfica.